Crinetics Pharmaceuticals Inc. announced the initiation of the CALM-CAH Phase 3 clinical trial evaluating atumelnant, an investigational oral adrenocorticotropic hormone (ACTH) receptor antagonist, for the treatment of classic congenital adrenal hyperplasia $(CAH)$ in adults. The first patient has been dosed in this pivotal, randomized, placebo-controlled study, which aims to assess atumelnant's ability to reduce excess adrenal androgens and improve glucocorticoid use. The trial builds on positive results from a previous Phase 2 study, which demonstrated reductions in key disease biomarkers and other clinical measures. Results from the Phase 3 study will be presented in the future.